Latest Woolsey Pharmaceuticals News & Updates

See the latest news and media coverage for Woolsey Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Woolsey Pharmaceuticals

Neurodegenerative disease treatment developer

woolseypharma.com

Last updated Today

Latest news about Woolsey Pharmaceuticals

In short: Woolsey Pharmaceuticals advanced its BRAVYL ALS program through a Series B extension and expanded clinical trials following positive Phase 2a data.

Company announcements

27 February 2025 Woolsey Pharmaceuticals

Woolsey Pharmaceuticals completes Series B extension

Funds advance BRAVYL ALS program. Completed high-dose enrollment; NfL decreased 15%; TDP-43 pathology reduced. Data expected June 2025.

10 January 2025 Woolsey Pharmaceuticals

Woolsey Pharmaceuticals secures U.S. patent claims for BRAVYL in ALS

USPTO grants claims covering fasudil treatment of ALS and NfL reduction. It adds to existing patents on formulations and sporadic ALS.

9 December 2024 Woolsey Pharmaceuticals

Woolsey reveals BRAVYL reduces TDP-43 spread in ALS patients

Lab findings show 60% reduction in aggregation and cytoplasmic redistribution after 6 months treatment. Presented at ALS/MND Symposium.

12 November 2024 Woolsey Pharmaceuticals

Woolsey Pharmaceuticals completes patient recruitment for high-dose ALS study cohort

Recruitment finished for 300 mg/day cohort (n=31) in REAL study of BRAVYL® after promising results at 180 mg/day, including 15% NfL decrease. Results expected mid-2025.

Media coverage

Never miss news about Woolsey Pharmaceuticals

Track Woolsey Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.